January 31, 2019 — Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich Teleport Microcatheter (Teleport), which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance.
Microcatheters are used to provide support and safe guidewire exchange during complex cardiovascular procedures. Teleport is a new generation microcatheter designed for deliverability and support, with a unique and robust tip designed to enable access in the most challenging lesions, according to the company.
Annapoorna S. Kini, M.D., director of the cardiac catheterization laboratory at Mount Sinai Medical Center, New York, and Emmanouil Brilakis, M.D., Ph.D., FACC, FAHA, FESC, FSCAI, interventional cardiologist at Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, treated the first U.S. patients with Teleport.
“I am excited and honored to be the first to use Teleport microcatheter in the United States. Teleport allowed me to deliver the microcatheter easily through tortuous coronary vasculature while maintaining catheter position for guidewire exchange treating a complex chronic total occlusion,” said Kini.
“I had the opportunity to use the Teleport Microcatheter in Europe and was impressed by its balance of deliverability and support. Teleport’s robust tip design is unique, enabling access to tight lesions while providing the torqueability necessary to treat very challenging lesions. I’m excited to have this device available to treat my patients here in the United States,” said Brilakis.
For more information: www.orbusneich.com
May 13, 2026 
